Dupilumab SAR231893 (REGN668)
EFC14146
Phase 3 small_molecule completed
Quick answer
Dupilumab SAR231893 (REGN668) for Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) is a Phase 3 program (small_molecule) at Regeneron UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed